According to a recent research report titled ‘GCC Oncology/Cancer Drugs Market Analysis, 2020’, available with Market Study Report, global GCC oncology/cancer drugs industry market is anticipated to register a healthy growth rate over 2020-2025.
 

As per the report findings, increasing pool of cancer patients and growing number of initiatives to reduce cancer-related deaths are the key factors driving the growth of GCC oncology/cancer drugs market. Moreover, rising government expenditure towards healthcare infrastructure development is boosting the industry growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3114610/
 

Based on therapy, GCC oncology/cancer drugs from targeted therapy is expected to witness tremendous gains during the forecast period, largely driven by mounting cases of breast cancer. Targeted therapy is commonly used for breast cancer treatment by targeting cellular processes to curb the growth of cancerous cells. High efficacy and survival rates associated with the therapy is compelling patients to opt for this option.
 

Elaborating on the application spectrum, GCC oncology/cancer drugs industry from breast cancer segment is expected to grow considerably in the coming years as this cancer form is among the leading causes of death among women in the region. Increasing government efforts to boost development & production of oncology drugs for breast cancer, along with several breast cancer awareness and prevention programs are catalyzing the segment growth.
 

Considering the geographical bifurcation, GCC oncology/cancer drugs market size spans across Saudi Arabia, UAE, Oman, Kuwait, Bahrain, and Qatar. Among these nations, UAE is likely to showcase strong growth trends in the forthcoming years on account of ongoing development of healthcare infrastructure coupled with launch of numerous breast cancer awareness campaigns and government initiatives. In fact, UAE aims to bring down cancer mortalities to about 64.2 per 100,000 of the population by the year 2021, cites The UAE National Health Agenda 2021.
 

Companies that account for majority of GCC oncology/cancer drugs industry share are Astellas MENA/SSA, Amgen, Inc., Bayer Middle East FZE, AstraZeneca Gulf FZ LLC, AbbVie Biopharmaceuticals GmbH, Merck Serono Middle East FZ-Ltd., Pfizer International Corp., Johnson & Johnson Middle East FZ LLC, and F. Hoffmann-La Roche AG.